We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
Read MoreHide Full Article
Hologic, Inc. (HOLX - Free Report) has been gaining from a slew of buyouts. Its slew of regulatory approvals has also been impressive. Its robust preliminary results for first-quarter fiscal 2021 buoy optimism. However, downsides may result from a stiff competitive landscape and foreign exchange headwinds.
Over the past year, the Zacks Rank #1 (Strong Buy) stock has gained 40.1% compared with 22.4% growth of the industry and 14.9% rise of the S&P 500.
The renowned provider of medical imaging systems and surgical products, catering to women’s healthcare needs, has a market capitalization of $19.56 billion. The company projects 17.4% growth for the next five years and expects to maintain strength in its business segments. The company surpassed estimates in three of the trailing four quarters and broke even in one, the average surprise being 45.89%.
Let’s delve deeper.
Impressive Q1 Fiscal 2021 Results: We are upbeat about Hologic’s recently released preliminary results for first-quarter fiscal 2021. The company’s projection of a reported revenue growth of 89.3% (86.5% at constant exchange rate) looks impressive. Further, organic revenues (or revenues excluding divestitures and the Acessa acquisition) are projected at a stupendous level of 104%, further buoying optimism on the stock.
Acquisitions: Hologic has, of late, been gaining from a slew of buyouts. This raises our optimism on the stock. The recently completed acquisition of SOMATEX Medical Technologies GmbH, a well-known name in the biopsy site markers and localization technologies space, looks encouraging. Hologic also announced its plans to acquire Biotheranostics, Inc., a privately held commercial-stage company providing molecular diagnostic tests for breast and metastatic cancer. These buyouts are expected to significantly boost Hologic’s business across the globe.
Regulatory Approvals: We are upbeat about Hologic’s recent regulatory clearances. The company received the FDA’s approval for its Genius AI Detection technology. In November, Hologic received the FDA’s approval for its diagnostic claim for its HIV-1 (human immunodeficiency virus type 1) viral load monitoring assay. The same month, the company received the CE Mark for its new Genius Digital Diagnostics System.
In October, Hologic announced the amendment of the FDA’s Emergency Use Authorization that was initially received for its Aptima SARS-CoV-2 assay (that runs on the company’s fully automated Panther system) in May.
However, downsides might result from Hologic’s operation in a highly competitive industry, which includes giants like Siemens. The FDA’s decision to re-classify FFDM devices to class II from class III makes it easier for all medical devices companies to introduce similar products in the market. Subsequently, the approval process for class II devices will require 510(k) clearance, rather than the lengthy premarket approval application. This will enable easier approval in the United States, thus intensifying competition among medical device companies.
Hologic faces significant business challenges owing to unfavorable foreign currency impacts. This persistent issue has been adversely affecting the company’s overall performance over the past few quarters.
Estimate Trend
Hologic has been witnessing a positive estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 65.6% north to $7.17.
The Zacks Consensus Estimate for first-quarter fiscal 2021 revenues is pegged at $1.32 billion, suggesting 55.7% growth from the year-ago reported number.
Other Key Picks
A few other top-ranked stocks from the broader medical space are Omnicell, Inc. (OMCL - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Patterson Companies, Inc. (PDCO - Free Report) .
IDEXX’s long-term earnings growth rate is estimated at 15.8%. It currently carries a Zacks Rank #2 (Buy).
Patterson Companies’ long-term earnings growth rate is estimated at 11.1%. The company presently carries a Zacks Rank #2.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Shutterstock
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
Hologic, Inc. (HOLX - Free Report) has been gaining from a slew of buyouts. Its slew of regulatory approvals has also been impressive. Its robust preliminary results for first-quarter fiscal 2021 buoy optimism. However, downsides may result from a stiff competitive landscape and foreign exchange headwinds.
Over the past year, the Zacks Rank #1 (Strong Buy) stock has gained 40.1% compared with 22.4% growth of the industry and 14.9% rise of the S&P 500.
The renowned provider of medical imaging systems and surgical products, catering to women’s healthcare needs, has a market capitalization of $19.56 billion. The company projects 17.4% growth for the next five years and expects to maintain strength in its business segments. The company surpassed estimates in three of the trailing four quarters and broke even in one, the average surprise being 45.89%.
Let’s delve deeper.
Impressive Q1 Fiscal 2021 Results: We are upbeat about Hologic’s recently released preliminary results for first-quarter fiscal 2021. The company’s projection of a reported revenue growth of 89.3% (86.5% at constant exchange rate) looks impressive. Further, organic revenues (or revenues excluding divestitures and the Acessa acquisition) are projected at a stupendous level of 104%, further buoying optimism on the stock.
Acquisitions: Hologic has, of late, been gaining from a slew of buyouts. This raises our optimism on the stock. The recently completed acquisition of SOMATEX Medical Technologies GmbH, a well-known name in the biopsy site markers and localization technologies space, looks encouraging. Hologic also announced its plans to acquire Biotheranostics, Inc., a privately held commercial-stage company providing molecular diagnostic tests for breast and metastatic cancer. These buyouts are expected to significantly boost Hologic’s business across the globe.
Regulatory Approvals: We are upbeat about Hologic’s recent regulatory clearances. The company received the FDA’s approval for its Genius AI Detection technology. In November, Hologic received the FDA’s approval for its diagnostic claim for its HIV-1 (human immunodeficiency virus type 1) viral load monitoring assay. The same month, the company received the CE Mark for its new Genius Digital Diagnostics System.
In October, Hologic announced the amendment of the FDA’s Emergency Use Authorization that was initially received for its Aptima SARS-CoV-2 assay (that runs on the company’s fully automated Panther system) in May.
However, downsides might result from Hologic’s operation in a highly competitive industry, which includes giants like Siemens. The FDA’s decision to re-classify FFDM devices to class II from class III makes it easier for all medical devices companies to introduce similar products in the market. Subsequently, the approval process for class II devices will require 510(k) clearance, rather than the lengthy premarket approval application. This will enable easier approval in the United States, thus intensifying competition among medical device companies.
Hologic faces significant business challenges owing to unfavorable foreign currency impacts. This persistent issue has been adversely affecting the company’s overall performance over the past few quarters.
Estimate Trend
Hologic has been witnessing a positive estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 65.6% north to $7.17.
The Zacks Consensus Estimate for first-quarter fiscal 2021 revenues is pegged at $1.32 billion, suggesting 55.7% growth from the year-ago reported number.
Other Key Picks
A few other top-ranked stocks from the broader medical space are Omnicell, Inc. (OMCL - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Patterson Companies, Inc. (PDCO - Free Report) .
Omnicell’s long-term earnings growth rate is estimated at 16%. The company presently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX’s long-term earnings growth rate is estimated at 15.8%. It currently carries a Zacks Rank #2 (Buy).
Patterson Companies’ long-term earnings growth rate is estimated at 11.1%. The company presently carries a Zacks Rank #2.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>